跳至主要内容
临床试验/NCT05339633
NCT05339633已完成1 期

An Open Label Phase 1 Study in Healthy Adult Female Subjects to Determine the Mass Balance Recovery, Absorption, Metabolism, and Excretion of [14C]-D-0502 Following Single Oral Dose Administration

InventisBio Co., Ltd1 个研究点 分布在 1 个国家目标入组 8 人开始时间: 2022年3月29日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
8
试验地点
1
主要终点
Radiolabel recovery

研究概览

简要总结

An Open Label Phase 1 Study in Healthy Adult Female Subjects to Determine the Mass Balance Recovery, Absorption, Metabolism, and Excretion of [14C] D-0502 Following Single Oral Dose Administration

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Other
盲法
None

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Healthy adult female volunteers not of child-bearing potential between the ages of 18 and
  • Other inclusion criteria will be reviewed by the Principal Investigator.

排除标准

  • History or presence of any condition or prior surgery that, in the opinion of the Investigator, poses a significant risk to subject safety and/or achievement of study objectives
  • Clinically significant abnormal medical history, or any abnormal findings on physical examination, vital signs, ECG, or laboratory tests
  • Other exclusion criteria will be reviewed by the Principal Investigator.

研究组 & 干预措施

Single Dose

Other

All study subjects will receive a a single oral dose of radiolabeled microtracer of D-0502 following an overnight fast

干预措施: [14C]-D-0502 (Drug)

结局指标

主要结局

Radiolabel recovery

时间窗: 14 days

To assess the mass balance (i.e., cumulative excretion in urine and feces) of D 0502 and the percentages of radiolabel recovered in urine and feces following administration of a single oral dose of D-0502/5 microcuries (µCi) \[14C\] D-0502 in healthy, adult female subjects

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Study in Healthy Adult Female Subjects | 临床试验